摘要
通过解读一例临床病例,简要介绍二肽基肽酶-4(dipeptide peptidase-4,DPP-4)抑制剂/二甲双胍固定剂量复方(fixed dose combination,FDC)制剂的有效性、安全性以及作用机制。DPP-4抑制剂通过提高内源性胰高糖素样肽-1(glucagon like peptide-1,GLP-1)浓度而发挥促进胰岛素分泌和抑制胰高糖素分泌即改善胰岛素抵抗的作用;二甲双胍主要改善胰岛素抵抗,也具有促进GLP-1分泌和抑制DPP-4活性的作用。DPP-4抑制剂/二甲双胍FDC针对2型糖尿病的病理生理缺陷,发挥降糖机制互补、协同增效的作用,既能简化治疗方案、有效控制血糖,也具有良好的安全性,适合于2型糖尿病患者的早期治疗。
Through clinical case interpretation, brief introduction of the dipeptide base peptidase-4 （DPP-4） inhibitors/metformin fixed dose combination （fixed dosed combination, FDC） preparation of effectiveness, safety, and the mechanism of action were discussed. DPP-4 inhibitors could increase the endogenous glucagon like peptide 1 （glp-1） concentration and promote insulin secretion, however fail to suppress glucagon secretion that improves the effect of insulin resistance; Metformin is mainly to improve insulin resistance, also promote glp-1 secretion and inhibit the activity of DPP-4. DPP-4 inhibitors/metformin combination therapy play an important role in the treatment of type 2 diabetes, because it could effectively control blood glucose level, also has good safety, thus it is suitable for early treatment of patients with type 2 diabetes.
出处
《药品评价》
CAS
2016年第7期42-46,共5页
Drug Evaluation
